SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending due to active investor speculation surrounding potential buyout rumors and an aggressive share buyback program that continues to reduce the float. The community remains deeply divided, with many bulls highlighting the stock's low price-to-earnings multiple as a deep-value opportunity, while frustrated traders express ongoing concern over stagnant price action and the company's competitive positioning.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing significant investor attention as the community debates its long-term potential in the MS market, focusing on the successful commercial launch of Briumvi and the strategic implications of upcoming subcutaneous dosing data. Discussions center on whether the company's growth trajectory and pipeline expansion make it a prime candidate for a high-premium buyout, or if management will continue building the business independently.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing heightened volatility and sharp price swings as investors weigh the company's massive cloud backlog and AI infrastructure investments against broader market concerns over tech-sector valuations and debt. The community is actively debating whether recent pullbacks represent a temporary shakeout of retail investors ahead of highly anticipated earnings, or if the stock is being unfairly penalized by institutional rotation and broader macro-driven selling.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as shares rally following a surge in May prediction market volumes, fueling community debate over the platform's role in future growth. Investors remain divided, with bulls highlighting expansion into new states as a long-term catalyst, while vocal critics focus on the stock's recent performance and ongoing management concerns.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors weigh its role as a critical supply chain partner to SpaceX and other aerospace giants against concerns over cash burn and potential dilution. The community remains deeply divided, with bulls pointing to the company's technical moats and anticipated earnings catalysts, while bears focus on high volatility, short interest dynamics, and the company's ongoing need for capital.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing significant volatility as market participants debate its role as a hedge against inflation and geopolitical uncertainty amid conflicting reports on international conflicts and aggressive selling pressure. The community remains deeply divided, with some investors aggressively accumulating on dips citing long-term industrial demand for electrification and AI, while others argue the metal is stuck in a corrective phase following a period of over-optimistic speculation.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as investors weigh strong institutional interest in its growing data center infrastructure against ongoing concerns regarding the CEO's communication strategy. While community members highlight the massive potential of the Helios campus, many are actively debating whether the stock is undervalued compared to its peers or if it remains held back by its heavy historical ties to crypto volatility.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is currently capturing investor attention as a structural outlier, holding steady at its gamma flip level while large-cap tech faces systematic repricing and heightened volatility. The market remains intensely focused on upcoming inflation data and potential Federal Reserve policy shifts, with traders closely debating whether the current rotation signals a rotation into small caps or a broader defensive positioning ahead of key macro catalysts.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp (UEC) is trending as investors focus on the company's production ramp-up at its Burke Hollow and Christensen Ranch projects amidst the broader nuclear energy sector's role in powering AI data centers. While the community is actively debating the stock's recent price volatility and institutional activity, sentiment remains heavily tied to the company's debt-free balance sheet and its strategic positioning within the domestic nuclear fuel supply chain.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as shares reach five-year highs following a significant patent extension for its lead drug, MIPLYFFA, through 2041. The community is actively discussing the company's strong fundamental position, analyst price target upgrades, and speculation regarding a potential buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged tosubmit their information immediately. You may also...

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.read more...

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations PR Newswire NEW YORK, June 3, 2026 SEC filings reflected...

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? 

Equity

The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology. 


Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) PR...

FULC Stock Crashes After Hours: What Investors Need To Know

Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.read more...

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk 

Fulcrum discontinued development of its lead candidate, pociredir, for sickle cell disease. 


After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

FULCFulcrum Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FULC News